Here's something you might be interested in.
Biotech Vical stock is soaring more than 29% to $2.84 this morning (May 21) as the company announced that it has developed a prototype vaccine against the swine flu virus, has begun testing on animals and could move to human trials if it gets adequate financing. The company said it has a cooperative arrangement with the U.S. Navy. The company's president this morning rang the bell to open trading on Nasdaq. Investors should be wary of quick stock moves based on publicity about a possible drug for a disease that is widely feared.
Biotech Vical stock is soaring more than 29% to $2.84 this morning (May 21) as the company announced that it has developed a prototype vaccine against the swine flu virus, has begun testing on animals and could move to human trials if it gets adequate financing. The company said it has a cooperative arrangement with the U.S. Navy. The company's president this morning rang the bell to open trading on Nasdaq. Investors should be wary of quick stock moves based on publicity about a possible drug for a disease that is widely feared.